Conpany Plofile

Company Name SANSHO Co., Ltd.
Location 【Head office】
Momijigawa Building Suite. 401
2-15-8 Nihonbashi, Chuo-ku, Tokyo 103-0027 JAPAN

Tsukuba Sogyo Plaza 203
2-1-6 Sengen Tsukuba-city, IBARAKI 305-0047 JAPAN
Establishment January 15, 2008
Capital stock 10,000,000 JPY(As of February 28. 2022)
Total number of shares issued and outstanding 971 shares (778 shares of common stock and 193 shares of Class A shares)
Officers President and CEO      Toshiro Morohoshi
Chief Financial Officer     Toshimitsu Morita
Outside Director       Chi-Tai Chang
Outside Corporate Auditor   Takayuki Okabuchi
Science Advisory Board
Dr. Shigeyuki Wakitani   Director, Kouryoukai Hospital (Orthopedic Surgeon)
Dr. Koji Kawakami         Professor, Kyoto University School of Medicine       
Dr. Ikuko Masuda          Director, Department of Rheumatology and Orthopedics,                                       Jujo Kyoto Rehabilitation Hospital and Adjunct Lecturer, 
                                   Tokyo Women's Medical University
Dr. Kan Tsukahara         Associate Professor, Nagasaki University Graduate School
                                   of Medicine and Dentistry

Management Philosophy and Basic Policies

The corporate philosophy of SANSHO Corporation is 
to "contribute to the health and well-being of the world with cyclic phosphatidic acid (cPA).

In order to realize our corporate philosophy, we will steadily and faithfully advance our research and development activities and strive to deliver necessary medicines to the medical community as soon as possible. 

Background of Business Development

SANSHO was established on January 15, 2008 with the aim of conducting a drug discovery business based on the intellectual property related to an invention by Professor Emeritus Kimiko Murofushi of the Faculty of Science, Ochanomizu University, a national university corporation.

Toshiro Morohoshi, the current Representative Director, has been collaborating with Professor Murofushi since the late 1980s at Asahi Kasei Pharma Corporation and Sosei Corporation, where he was employed at the time , and established SANSHO to develop new drugs using cyclic phosphatidic acid (cPA), which she discovered.


Jan. 2008 Establishment of the Company
Oct. 2013 Out-licensed 2Carba cycle phosphatidic acid to Orient Europharma Co.,Ltd. in Taiwan
Apr. 2017 Obtained IND from US FDA for the 2 Carba cyclic phosphatidic acid (synthetic, drug)
 Sep. 2017Obtained IND from Taiwan FDA for the 2 Carba cyclic phosphatidic acid (synthetic, drug)
Feb. 20182Carba cyclic phosphatidic acid (synthetic form, drug) Phase I clinical trial (Phase 1/b) started in Taiwan (indication: osteoarthritis of the knee)
 May. 2019Series A financing from venture capital firms
 Jul. 2019Opened our research laboratory at Yokohama Venture Plaza at Tokyo Institute of Technology in Yokohama, Kanagawa Prefecture
 Oct. 20212Carba cyclic phosphatidic acid (synthetic, drug) Phase I clinical trial (Phase 1/b) completed in Taiwan (Indication: osteoarthritis of the knee)
May 2022 Moved our research laboratory to Tsukuba Founder's Plaza in Tsukuba City, Ibaraki Prefecture
As of May 31, 2022